SCHEMBL10248867

SCHEMBL10248867

Cc1ccc2c(c1)nc(-c1ccncc1OCc1ccccc1)n2C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.44
ATM Q13315 1/20 0.43
MAPT P10636 1/20 0.42
RHEB Q15382 1/20 0.42
LRRK2 Q5S007 1/20 0.41
PTGES O14684 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
IKBKB O14920 2/20 0.41
BUB1 O43683 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
STAT3 P40763 1/20 0.40
HTT P42858 1/20 0.40
PDE2A O00408 1/20 0.40
PDE10A Q9Y233 1/20 0.40
ACSS2 Q9NR19 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL169889 0.87 LRRK2 (0.43) SMN1; SMN2POLBATMRHEBLRRK2
SCHEMBL10248909 0.85 SMN1; SMN2 (0.48) SMN1; SMN2POLBATMMAPTNPC1
SCHEMBL10249340 0.85 BRD4 (0.41) SMN1; SMN2RHEBLRRK2IKBKBBUB1
SCHEMBL10248845 0.83 SMN1; SMN2 (0.46) SMN1; SMN2POLBATMMAPTBUB1
SCHEMBL10249052 0.82 MAPT (0.46) SMN1; SMN2POLBATMMAPTNPC1
SCHEMBL10249106 0.82 SMN1; SMN2 (0.46) SMN1; SMN2POLBATMMAPTNPC1
SCHEMBL10249174 0.81 SMN1; SMN2 (0.45) SMN1; SMN2POLBATMMAPTPTGES
SCHEMBL10249166 0.81 SMN1; SMN2 (0.61) SMN1; SMN2POLBATMMAPTNPC1
SCHEMBL10249209 0.80 SMN1; SMN2 (0.43) SMN1; SMN2POLBATMMAPTNPC1
SCHEMBL10248912 0.78 SMN1; SMN2 (0.48) SMN1; SMN2POLBATMMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885ATM 4476/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885ATM 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.